MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of short-term...
$130,277K
Net cash (used in)
investing activities
$56,781K
Canceled cashflow
$73,496K
Net (decrease)
increase in cash and cash...
-$44,417K
Canceled cashflow
$56,781K
Stock-based compensation
expense
$9,261K
Accounts payable
$7,176K
Prepaid expenses and
other assets
-$5,489K
Loss on
extinguishment of loan payable
-$1,557K
Amortization of debt issuance
costs and discount
$179K
Non-cash lease expense
$69K
Proceeds from the
exercise of stock options
$3,371K
Purchase of short-term
and long-term...
$73,496K
Net cash used in
operating activities
-$67,171K
Canceled cashflow
$23,731K
Net cash provided by
financing activities
-$34,027K
Canceled cashflow
$3,371K
Net loss
-$81,566K
Accrued expenses and
other current...
-$6,408K
Net amortization of
premiums and discounts on...
$2,429K
Fair value change in
warrant liability
-$400K
Operating lease liability
-$73K
Repayment of loan payable
$37,398K
Back
Back
Cash Flow
source: myfinsight.com
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)